PMN.TO - Promis Neurosciences Inc


#102

ProMIS Neurosciences successfully completes CDN$2.7 million private placement

Des directeurs ont participé au placement privé :

Directors of the Company purchased a total of 690,000 units or CDN$100,050 of the placement.

Divulgation : J’ai aussi participé au placement


#103

J’ai discuté avec le PDG de ProMIS il y a environ 2 semaines.

Étant donné les excellents résultats obtenus avec PMN 310, ils ont décidé de prioriser ce programme. Tel que mentionné plus haut, on parle d’environ $10M pour se rendre jusqu’au début des études cliniques pour cette seule molécule. Il y aura d’autres financements dans le futur, cela dit, c’est bien de les voir lever $2.7M aussi rapidement et de voir les initiés participer à nouveau (ils ont investi dans chacun des financements depuis leur arrivée en poste).

Le prochain catalyseur sera l’étude de cohorte. On risque d’en apprendre beaucoup sur la prévalence de chacune des souches toxiques d’Amyloid beta.


#104

ProMIS Neurosciences Announces Fiscal 2016 Annual Results


#105

ProMIS Neurosciences Announces Appointment of Daniel Geffken as Chief Financial Officer


#106

ProMIS Neurosciences announces presentation and expert panel participation at the Neuroscience Biopartnering and Investment Forum

Toronto, Ontario – March 28, 2017 – ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its participation in the 2nd Annual Neuroscience Biopartnering and Investment Forum conference organized by Sachs Associates and held at the New York Academy of Sciences on March 27, 2017.

ProMIS Executive Chairman, Eugene Williams, presented an update and overview on the company’s rapid progress and future outlook, and also contributed as a member of the expert panel entitled “Advances in Alzheimer’s Disease”.

“Following on from the Company’s successful fund raise announced in February of this year, ProMIS will focus on progressing the development of its antibody program targeting toxic, prion-like forms of Amyloid beta, a root cause of Alzheimer’s. Our lead development product, PMN310, is on track for IND submission at the end of 2018”, stated Williams. “Furthermore, there is a substantial body of evidence from prior clinical trials in AD that targeting specifically the toxic, prion-like strains of Amyloid beta, while avoiding targeting of Amyloid beta monomer and plaque, will lead to best in class disease modifying therapy”.

The Company overview presented at the meeting is available here:


#107

ProMIS Neurosciences announces overview of first quarter 2017 progress and outlook for near termvalue creation

TORONTO, March 30, 2017 /CNW/ - ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, released today management’s review of the first quarter of 2017, which included a review of Q1 accomplishments, a status update on ongoing programs, and its outlook for near term value creation.

Key highlights of the quarterly update include:

Numerous studies underway and on track to further validate that ProMIS is building a ‘best in class’ portfolio of therapies targeting toxic, prion-like forms of Amyloid beta, a root cause of Alzheimer’s;
Results announced in January for lead product PMN310 showed prevention of short term memory loss in a well-validated mouse model. ProMIS’s other four monoclonal antibodies (mAbs) are undergoing evaluation in the same model, with results expected over the coming months;
PMN310 on track for IND submission (clinical trial initiation) in late 2018;
Cohort study underway, evaluating presence and prevalence of ProMIS mAb targets in cerebrospinal fluid (CSF) and blood from Alzheimer’s patients, with initial readout expected in the coming months;
Diagnostics development underway and on track; goal is to create diagnostics to detect different toxic oligomer strains of Amyloid beta in both CSF and blood;
Discovery programs for TDP43 and Tau, two highly valued targets in neurodegenerative disease and dementia, on track with confirmation of targets and patent submissions expected soon.
“2017 is shaping up to be a very important year for ProMIS, and the year is off to a great start. All our programs are progressing well, and external events continue to support our scientific strategy”, said Eugene Williams, Executive Chairman.

“Recently announced results of major clinical trials with competitor products in Alzheimer’s strongly support ProMIS’ differentiation”, stated ProMIS President and CEO, Dr. Elliot Goldstein. “We remain very confident that our mAb programs focused on selectively targeting the toxic, prion-like forms of Amyloid beta will lead to ‘best in class therapy’ and significant value creation”.

Quarterly Update: Q1 2017


#108

ProMIS Neurosciences announces results presented at the 13th International Conference on Alzheimer’s and Parkinson’s diseases held in Vienna, Austria

TORONTO, April 12, 2017 (GLOBE NEWSWIRE) – ProMIS Neurosciences (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announces results of its recent therapeutic developments presented at the 13th International Conference on Alzheimers (AD) and Parkinsons diseases held in Vienna, Austria, from March 29 to April 2nd. This year`s conference was devoted to mechanisms, clinical strategies and promising treatments of neurodegenerative diseases.

“Results presented at the 13th International AD/PD conference confirmed ProMIS monoclonal antibodies (mAbs) selectively target five distinct epitopes on misfolded strains of toxic Amyloid beta (Aß), without targeting Aß monomer or plaque”, stated Dr. Elliot Goldstein, ProMIS President and CEO. “Prior AD clinical trials with mAbs targeting monomer (e.g. solanezumab) have been ineffective, due to target distraction, whereas mAbs targeting plaque (e.g. aducanumab) are associated with the dose limiting toxicity of brain swelling. By specifically targeting only the toxic forms of Aß, we anticipate ProMIS mAbs will demonstrate a best in class product profile with respect to both efficacy and tolerabilty”.


#109

petit signal technique ce matin, semble vouloir breakout


#110

J’allais le mentionner…5-6x le volume moyen aujourd’hui avec 1.1M d’actions transigées

edit : J’ai pas vu de news ou rien…quelqu’un veut bâtir une position…+28% sur 2.5M de volume


#111

Le marché anticipe de bons résultats. Rendu à 0,315$ sur 1.5M de volume.

ProMIS Neurosciences to announce results in a presentation at the 2017 American Association of Neurology annual meeting

TORONTO, April 27, 2017 /CNW/ - ProMIS Neurosciences (“ProMIS” or the “Company”, TSE ticker PMN.TO), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced it will present results on its recent Alzheimer’s disease (AD) therapeutic developments on Friday, April 28th at the 2017 annual meeting of the American Academy of Neurology (AAN), held in Boston, MA, from April 22-28.

“Based on our results presented at this year’s AAN annual meeting we anticipate ProMIS monoclonal antibodies (mAbs), selectively targeting toxic forms of Amyloid beta (Aβ), will demonstrate a ‘best in class’ product profile for treatment of AD,” stated Dr. Elliot Goldstein, ProMIS President and CEO. “Indeed, by virtually no binding to Aβ monomer, ProMIS mAb products should allow improved efficacy by avoiding targeting of this abundant, non-toxic form of Aβ. Similarly, by not targeting plaque which is associated with neurovascular edema (‘brain swelling’), a dose limiting adverse event, we anticipate improved safety and tolerability for our products”.


#112

Je ne vois pas ce qu’il y a de nouveau dans les résultats qui seront annoncés à cette conférence. L’étude de cohorte sera publiée en mai.

À mon avis, le titre continue sur son momentum des derniers jours et la nouvelle a bien été accueillie car il s’agit d’une conférence très réputée.


#113

Je voulais aussi parler des résultats de la cohorte qu’on devrait voir d’ici la fin mai (selon Michael Bigger). Selon ma compréhension, rien de nouveau depuis la présentation de Vienne au milieu du mois.

Achat d’initié cette semaine :


#114

ProMIS Neurosciences Announces Q1 2017 Quarterly Results

TSX: PMN

TORONTO, May 9, 2017 /CNW/ - ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three months ended March 31, 2017.

“We continue to make significant progress on our Alzheimer’s disease (AD) program” said Dr. Elliot Goldstein, ProMIS CEO. “Our priorities are to further advance development of ProMIS’ lead product, PMN 310, with a goal of IND submission by the end of 2018, to complete a cohort study to determine the prevalence of different prion strains of Amyloid beta in AD, and to initiate development of effective AD diagnostics for detection of toxic prion strains in cerebrospinal fluid (CSF) or blood.”

ProMIS also announced continued work on two new drug development programs to identify novel therapeutic targets on Tau for AD, and TDP43 for Amyotrophic Lateral Sclerosis (ALS) and frontotemporal dementia (FTD), representing additional opportunities to apply its complementary platform technologies.

Recent Corporate Highlights

PMN 310, declared lead development product, on track for IND submission at the end of 2018.

Advanced programs to identify novel therapeutic targets on toxic strains of the protein Tau for AD, and on protein TDP43 for ALS and FTD;

In February 2017, completed private placements providing total gross proceeds of approximately $2,700,000;

Appointed Mr. Anthony Giovinazzo to the Board of Directors.

Announced Mr. Daniel Geffken to the position of Chief Financial Officer.


#115

Posté sur twitter par @maxwellhouse99

Annual Award to Recognize the Most Significant Contributor to Canada’s Healthcare Industry

TORONTO, May 8, 2017 – Bloom Burton & Co. (“Bloom Burton”), Canada’s leading healthcare-specialized investment banking firm, is pleased to announce the three finalists for the inaugural Bloom Burton Award.

The finalists are:

  • Allen Eaves, Founder, President and CEO of STEMCELL Technologies:

  • Anthony Giovinazzo, former President and CEO of Cynapsus Therapeutics;

  • Cameron Piron, Founder and President of Synaptive Medical.

Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest impact in Canada’s innovative healthcare industry. Nominees are accepted from the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, healthcare services or healthcare IT sectors, and from all therapeutic indications and stages of development. Nominations were accepted from the public-at- large between January 1 and March 31, 2017. All three finalists, along with their family and friends, will be invited to and celebrated at the Bloom Burton Award Gala on September 14, 2017 at the Four Seasons Hotel in Toronto, Ontario, Canada. The winner will receive a $50,000 cash prize, while the other two finalists will each receive $25,000. A limited number of tickets are available for industry sponsors and individuals.


#116

ProMIS Neurosciences Designates PMN350 its Second Lead Product for Development in Alzheimer’s Disease

TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 24, 2017 – ProMIS Neurosciences, a company focused on discovery and development of precision treatments for neurodegenerative diseases, today announced that it has designated PMN350 – a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers (AβO) – as the Company’s second lead product for Alzheimer’s disease (AD).

“We previously demonstrated that PMN310, our first lead product for development in Alzheimer’s disease, presents the optimal target profile of selectively binding prion-like forms of AβO, inhibiting both their propagation and neurotoxicity,” stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. “We have now achieved a significant development milestone by demonstrating that PMN350, our second AD lead product directed against a different target on toxic AβO, also displays the optimal target product profile in both in vitro and in vivo tests.”

The neuroprotective effect of PMN350 was investigated at SynAging, SAS, a leading contract research organization (CRO) specializing in neurodegenerative diseases. Injection of prion-like forms of AβO (also called toxic soluble oligomers) into the brains of mice causes a neurological deficit that can be assessed in a memory-behavior test called novel object recognition. Normal mice exposed to an object remember the familiar object when re-exposed to it and spend more time exploring a newly introduced object. In contrast, AβO-injected mice lose the ability to discriminate between known and novel objects and spend equivalent amounts of time exploring both. Results obtained in this assay showed that administration of PMN350 to mice completely prevented the cognitive impairment caused by toxic oligomers. Furthermore, the observed cognitive benefit of PMN350 was correlated with a statistically significant improvement of two synaptic biomarkers (SNAP25, PSD95) and a biomarker of inflammation (TNFα) measured in hippocampal brain homogenates.

“We are pleased that our propriety discovery engine has produced a second lead product with the potential to treat Alzheimer’s,” commented Dr. Elliot Goldstein, ProMIS President and CEO. “With two lead development products, PMN310 and PMN350, each selectively addressing a different target (epitope) on toxic prion-like forms of amyloid-beta oligomers, we look forward to initial evaluation of their relative prevalence in cerebrospinal fluid samples from Alzheimer’s patients, thereby paving the way for a precision medicine approach to this devastating disease.”

About SynAging, SAS

SynAging focuses on disease-inducing protein aggregates which are involved in the earliest stages of proteopathic neurodegenerative diseases, like Alzheimer’s and Parkinson’s. Proteopathic diseases are those in which certain proteins become structurally abnormal, and thereby disrupt the function of cells, tissues and organs of the body. SynAging is a contract research organization based in Nancy, France, providing highly reproducible drug testing services, employing proprietary protein aggregates to initiate symptoms of neurodegenerative diseases in vitro and in vivo.


#117

ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia

Company files United States patent application for novel epitope target identified on misfolded forms of the protein TDP43

TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 31, 2017 – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the identification of a novel therapeutic epitope target on misfolded forms of TDP43, implicated in the development and progression of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The Company filed a provisional patent application for this target with the United States Patent Office on May 30, 2017.

Commenting on today’s announcement, Dr. Neil Cashman, ProMIS Chief Scientific Officer, stated: “Using our proprietary discovery engine, scientists at UBC and ProMIS identified both the sequence and conformational shape of this novel epitope target on misfolded TDP43 that plays a key role in ALS and frontotemporal dementia.”

TDP43 is present in every cell, and plays a critical role in the response of cells to oxidative stress. However, in ALS, FTD and other neurodegenerative diseases, TDP43 can lose its normal function, forming intracellular aggregates of misfolded TDP43 that disrupt cellular energy generation and normal protein degradation.

“Our goal is to selectively target misfolded TDP43 without disrupting the critical role that normally-folded TDP43 plays in cell biology,” stated Dr. Elliot Goldstein, ProMIS President and CEO. “We plan to create and validate monoclonal antibodies against misfolded TDP43 to select optimal therapeutic candidates for advancement into the clinic.”
Pursuant to its expanded license agreement with the University of British Columbia, ProMIS holds exclusive, worldwide license to this novel therapeutic target.


#118

(Nouvelle 5 juillet) [ProMIS Neurosciences to Present Preclinical Data from Alzheimer’s Disease Program at AAIC 2017]
(https://promisneurosciences.com/news/promis-neurosciences-present-preclinical-data-alzheimers-disease-program-aaic-2017/)

(Nouvelle 6 juillet) ProMIS Neurosciences’ Sponsored Research Agreement with University of British Columbia Receives Matching Grant from Canadian Institutes of Health Research


#119

ProMIS Neurosciences Announces CDN$3 Million Best-Efforts Private Placement


#120

C’est évident que Promis doit lever du capital et un discount au marché est attendu, mais je suis un peu surpris des demi-warrant à 0.30$ quand le titre se transige autour de ce montant depuis mi-avril.


#121

J’espérais mieux également… Un bought deal à de meilleures conditions. Il y a encore un certain scepticisme autour de la science de ProMIS. J’aimerais voir des investisseurs réputés prendre position dans le capital de la compagnie, mais pour ça il manque de données probantes. L’argent du financement va servir à avancer les travaux pré-cliniques sur PMN310 et PMN350, c’est le point positif!